Zoetis (ZTS) Intangibles (2012 - 2026)
Zoetis' (ZTS) quarterly Intangibles came in at $959.0 million in Q1 2026, down 11.37% year-on-year from $1.1 billion in Q1 2025, and down 3.91% on a QoQ basis from $998.0 million in Q4 2025.
Zoetis (ZTS) Intangibles (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Intangibles data on file, last reported at $959.0 million in Q1 2026.
- On a quarterly basis, Intangibles fell 11.37% year-over-year to $959.0 million in Q1 2026; TTM through Mar 2026 was $959.0 million, a 11.37% decrease from a year earlier, with the FY2025 full-year figure at $998.0 million, down 11.45% from the prior year.
- Intangibles for Q1 2026 stood at $959.0 million, down from $998.0 million in the prior quarter.
- Over the last five years, Intangibles for ZTS reached as high as $1.4 billion in Q1 2022 and fell as low as $959.0 million in Q1 2026.
- Historically, Intangibles has averaged $1.2 billion across 5 years, with a median of $1.3 billion in 2023.
- Across the five-year window, Intangibles climbed 5.99% in 2023 and fell 16.45% in 2025, its largest moves.
- Year by year, Intangibles stood at $1.4 billion in 2022, then slipped by 3.04% to $1.3 billion in 2023, then retreated by 15.77% to $1.1 billion in 2024, then slipped by 11.45% to $998.0 million in 2025, then slipped by 3.91% to $959.0 million in 2026.
- Per Business Quant data, the three most recent Intangibles figures were $959.0 million in Q1 2026, $998.0 million in Q4 2025, and $1.0 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 34.07 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.61 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 959.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 21.80 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 473.93 Mn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.48 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.23 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 78.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 959.00 Mn |
| Dec 31, 2025 | 998.00 Mn |
| Sep 30, 2025 | 1.04 Bn |
| Jun 30, 2025 | 1.08 Bn |
| Mar 31, 2025 | 1.08 Bn |
| Dec 31, 2024 | 1.13 Bn |
| Sep 30, 2024 | 1.19 Bn |
| Jun 30, 2024 | 1.23 Bn |
| Mar 31, 2024 | 1.30 Bn |
| Dec 31, 2023 | 1.34 Bn |
| Sep 30, 2023 | 1.40 Bn |
| Jun 30, 2023 | 1.25 Bn |
| Mar 31, 2023 | 1.31 Bn |
| Dec 31, 2022 | 1.38 Bn |
| Sep 30, 2022 | 1.32 Bn |
| Jun 30, 2022 | 1.39 Bn |
| Mar 31, 2022 | 1.43 Bn |
| Dec 31, 2021 | 1.47 Bn |
| Sep 30, 2021 | 1.57 Bn |
| Jun 30, 2021 | 1.64 Bn |